Study Phase 2

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of Recombinant Human Erythropoietin (Epoetin Alfa (PROCRIT®)) on Functional Outcomes in Anemic, Critically Ill, Trauma Subjects

Trial Information

Generic NameEpoetin alfaProduct NamePROCRIT®Therapeutic AreaBlood and Lymph ConditionsEnrollment192% Female36%% White64%
Product ClassColony-Stimulating FactorsSponsor Protocol NumberPR04-15-001 Data PartnerJohnson & JohnsonCondition StudiedAnemiaMean/Median Age (Years)33

Supporting Documentation

  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available
Additional Information

Please note: individual participant-level data are not available for this trial. Only the protocol, statistical analysis plan, and full clinical study report are available.


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.